Milestone Pharmaceuticals Inc
MIST1.760USD
+0.040+2.33%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
149.90MMarket Cap
LossP/E TTM
More Details of Milestone Pharmaceuticals Inc Company
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc Info
Ticker SymbolMIST
Company nameMilestone Pharmaceuticals Inc
IPO dateMay 09, 2019
CEOOliveto (Joseph)
Number of employees33
Security typeOrdinary Share
Fiscal year-endMay 09
Address420-1111 boul. Dr.-Frederik-Philips
CityMONTREAL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4M 2X6
Phone15143360444
Websitehttps://www.milestonepharma.com
Ticker SymbolMIST
IPO dateMay 09, 2019
CEOOliveto (Joseph)
Company Executives of Milestone Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Jeffrey Nelson
Mr. Jeffrey Nelson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Other
68.16%
Shareholders
Shareholders
Proportion
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Other
68.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.52%
Hedge Fund
14.43%
Venture Capital
6.24%
Research Firm
5.04%
Individual Investor
3.97%
Investment Advisor/Hedge Fund
3.95%
Private Equity
3.78%
Family Office
1.17%
Bank and Trust
0.02%
Other
44.87%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
118
42.48M
49.88%
+14.49M
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Simplify Asset Management Inc
7.96M
9.34%
+5.18M
+186.09%
Sep 30, 2025
Adage Capital Management, L.P.
6.98M
8.19%
+6.98M
--
Sep 30, 2025
Propel Bio Management, LLC
5.12M
6.02%
+4.27M
+502.93%
Jul 11, 2025
Trails Edge Capital Partners LP
3.83M
4.5%
-1.50M
-28.13%
Sep 30, 2025
OrbiMed Advisors, LLC
3.22M
3.78%
+3.22M
--
Sep 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
Morgan Stanley & Co. LLC
2.63M
3.09%
+1.81M
+221.87%
Sep 30, 2025
RTW Investments L.P.
2.51M
2.94%
--
--
Sep 30, 2025
Pathstone
1.00M
1.17%
+1.00M
--
Sep 30, 2025
Two Sigma Investments, LP
900.59K
1.06%
+900.59K
--
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Proportion8.04%
SPDR S&P International Small Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
